+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists



Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists



Bioorganic and Medicinal Chemistry 16(2): 981-994



A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPARalpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPARalpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPARalpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPARalpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055961182

Download citation: RISBibTeXText

PMID: 17964792

DOI: 10.1016/j.bmc.2007.10.007


Related references

Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Bioorganic & Medicinal Chemistry Letters 18(6): 2128-2132, 2008

A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5- -4-oxazolylbutyl-1,3-dioxane-r-2-carboxylic acid. Journal of Pharmacology & Experimental Therapeutics 309(3): 970-977, June 1, 2004

Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists. Bioorganic and Medicinal Chemistry 24(21): 5455-5461, 2016

Analysis of the critical structural determinant of species-selective peroxisome proliferator-activated receptor alpha -activation by phenylpropanoic acid-type PPARalpha agonists. Bioorganic & Medicinal Chemistry Letters 13(19): 3145-3149, 6 October, 2003

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators. Journal of Medicinal Chemistry 46(17): 3581-3599, 2003

A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides. Bioorganic and Medicinal Chemistry 20(2): 714-733, 2012

Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism. Biochimie 91(8): 1029-1035, 2009

7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. Journal of Medicinal Chemistry 52(21): 6835-6850, 2009

A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. Journal of Pharmacology and Experimental Therapeutics 309(3): 970-977, 2004

Selective peroxisome proliferator-activated receptoralpha modulators SPPARMalpha The next generation of peroxisome proliferator-activated receptor alpha-agonists. 2013

Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Molecular Pharmacology 58(3): 470-476, 2000

Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Molecular Cancer Therapeutics 6(5): 1588-1598, 2007

Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) alpha agonist; possible mechanism(s) of human PPARalpha selectivity of an alpha-substituted phenylpropanoic acid derivative (KCL). Chemical & Pharmaceutical Bulletin 52(3): 365-367, 2004

Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver. Journal of Biological Chemistry 276(45): 42485-42491, 2001

Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes. Drug Metabolism and Pharmacokinetics 25(1): 108-111, 2010